gilberto lopes (@GlopesMd) ranks #5 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 64 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: HARMONi-6, DeLLphi-305, TAISHAN-302. CMS Open Payments lists $28,812 in 2025 general payments.
At a Glance
- 61 posts naming a trial in 2026
- 33 trials discussed by name
- Lung Cancer: US #5, Global #7 · 64 physicians engaged
- Leading physician voice: #2 of 14 physicians on CHRYSALIS-2; #3 of 19 physicians on HARMONi-2
- Presented at WCLC 2026 in 2026
- CMS Open Payments lists $28,812 in 2025 general payments.
This Month
What gilberto lopes has posted in the last 30 days. Updated November 10, 2026.
PANKU-Lung01 at #ESMO26: promising phase III results for EGFR×HER3 bispecific ADC iza-bren after EGFR TKI. PFS: 11.1 vs 5.7 mo (HR 0.40). ORR: 60.2% vs 34.5%. OS immature. China-only trial; global validation and optimal sequencing remain important. #LungCancer https://t.co/HsUPcmZQ0W
PERSEE at #ESMO26: PD-L1 ≥50% advanced NSCLC. Pembrolizumab + chemo vs pembrolizumab alone: PFS: 16.1 vs 6.9 mo (HR 0.56) OS: 50.2 vs 29.9 mo (HR 0.77; not statistically significant) Grade ≥3 TRAEs: 54% vs 19% Better disease control, more toxicity. Individualize. #LungCancer
Two important TROP2 ADC trials at #ESMO26 — but both conducted in China. OptiTROP-Lung04: EGFRm NSCLC after EGFR-TKI progression. Sac-TMT vs platinum–pemetrexed (N=376): OS 25.9 vs 17.4 mo HR 0.69 (95% CI 0.54–0.89) A meaningful randomized survival benefit. #LCSM https://t.co/oVNG8kEEOY
OptiTROP-Lung06: 1L PD-L1-negative, EGFR/ALK-negative nonsquamous NSCLC. Sac-TMT + pembro vs chemo + pembro (N=455): PFS 15.0 vs 5.7 mo HR 0.49 (95% CI 0.36–0.65) OS encouraging but immature. Median follow-up only 9.7 mo. The major limitation: China-only populations.
🚨 Important EGFR-mutated NSCLC results at #ESMO26! Phase III SAFFRON (N=338): Osimertinib + savolitinib vs platinum–pemetrexed after osimertinib progression, with high MET overexpression and/or amplification. OS: 17.8 vs 12.9 mo HR 0.68 (95% CI 0.50–0.91) https://t.co/KF8sZMbyxb
🚨 Major KRAS G12C NSCLC results at #ESMO26! Phase III Krascendo 1 (N=338): divarasib vs sotorasib/adagrasib. OS: 17.7 vs 12.0 mo HR 0.56 (95% CI 0.41–0.78) PFS: 9.8 vs 5.7 mo HR 0.58 (0.44–0.76) An important randomized survival advance. #LCSM More from Krascendo 1: https://t.co/YwjhBFcDcJ
Who Amplifies gilberto lopes
Physicians who reposted gilberto lopes’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #5 | #7 | 64 | 108 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions gilberto lopes presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- WCLC 2026 · Abstract presentationDoes adding circulating tumor RNA to ctDNA improve detection of actionable alterations in NSCLC? (602 patients, real-world liquid biopsy)Source: @GlopesMd on X ↗
What Colleagues Are Saying About gilberto lopes
2026 posts by fellow physicians that mention @GlopesMd, quoted word for word.
Love this Lopes’ List! Great day 1 #ASCO26 #lcsm summary @GlopesMd! https://t.co/d9cOCskXBO
Dr. @GlopesMd leads a discussion on policy and how it truly impacts every aspect of lung cancer care. Need to think of implementation, risk reduction, access to care and therapeutics #WCLC26. https://t.co/xHmLY6MjMU
My first #selfie of @IASLC #WCLC26 🫁 at 7:20am first thing in the morning right before the policy workshop @GlopesMd spoke at! Grateful for your always helpful insights on projects we have worked on together 🙏🏼 And looking forward to continuing to work together and learn from you in the future!
Kicked off the official programme of @IASLC #WCLC26 with the our 8:00am session 🌅 WS04 discussing practical skills for engaging #policymakers on #lungcancer. Together with @GlopesMd, we had the opportunity to insights and experiences in describing what #policymakers need to hear. Thanks @LungPolicy for organising this session! @APCLC_2023 @apoddc @CUHKMedicine
Agreed, we now have 3 available options. My preference for TKD mutation is going to be towards Zongertinib (oral, high ORR 👇👇 @GlopesMd, AE profile). TDXd is still going to be used a good amount but for Her2 positive or over expressing tumors (rather than “TKD mutated”) https://t.co/xJkP2RCcxH
Thanks Kevin, excellent thought and yes this is an under appreciated aspect of cancer care. Also effects on sleep, exercise, diet under appreciated. The lung cancer doctors are an impressive group. I’m sure they’ll educate us both. @CharuAggarwalMD @FionnualaCrowle @FordePatrick @GlopesMd @FordePatrick @BalazsHalmosMD and many more Doing a great job with a lot of heart and Seoul this week
Trials gilberto lopes Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| HARMONi-6 | 5 | #14 of 74 | Jun 1, 2026 |
| DeLLphi-305 | 4 | #17 of 86 | Oct 24, 2026 |
| TAISHAN-302 | 4 | #8 of 26 | Sep 13, 2026 |
| CROWN | 4 | #6 of 36 | May 30, 2026 |
| SAFFRON | 3 | #15 of 50 | Oct 25, 2026 |
| KRASCENDO-1 | 3 | #8 of 49 | Oct 25, 2026 |
| REZILIENT3 | 3 | #7 of 27 | Sep 14, 2026 |
| ARROS-1 | 3 | #13 of 26 | Sep 14, 2026 |
| MAVERICK (SWOG S1827) | 3 | #5 of 33 | Sep 13, 2026 |
| ARTEMIS-008 | 3 | #6 of 20 | Sep 13, 2026 |
| CHRYSALIS-2 | 3 | #2 of 14 | May 30, 2026 |
| OptiTROP-Lung05 | 3 | #4 of 19 | May 30, 2026 |
| WU-KONG28 | 3 | #5 of 29 | May 30, 2026 |
| OptiTROP-Lung04 | 2 | #6 of 18 | Oct 26, 2026 |
| OptiTROP-Lung06 | 2 | #19 of 29 | Oct 26, 2026 |
| PAPILLON | 2 | #13 of 26 | Sep 14, 2026 |
| ADAURA | 2 | #17 of 41 | Aug 22, 2026 |
| TALAPRO-3 | 2 | #17 of 39 | May 31, 2026 |
| PROTEUS | 2 | #16 of 56 | May 31, 2026 |
| LIBRETTO-432 | 2 | #25 of 53 | May 30, 2026 |
| PANKU-Lung01 | 1 | #7 of 16 | Oct 27, 2026 |
| PERSEE (GFPC 01-2020) | 1 | #28 of 34 | Oct 27, 2026 |
| FLAURA2 | 1 | #16 of 25 | Oct 24, 2026 |
| ATOMIC | 1 | #8 of 9 | Oct 12, 2026 |
| DESTINY-Lung04 | 1 | #22 of 37 | Sep 14, 2026 |
| HARMONi-2 | 1 | #3 of 19 | Sep 13, 2026 |
| SOHO-01 | 1 | #5 of 8 | Sep 10, 2026 |
| HARMONi | 1 | #5 of 16 | Aug 27, 2026 |
| EVOKE-03 / KEYNOTE-D46 | 1 | #6 of 16 | Aug 21, 2026 |
| EMERALD3 | 1 | #13 of 18 | Jun 1, 2026 |
| RASolute 302 | 1 | #35 of 73 | May 31, 2026 |
| RAMPART | 1 | #5 of 8 | May 30, 2026 |
| ARACOG | 1 | #10 of 10 | May 30, 2026 |
gilberto lopes on HARMONi-6
RT @JacobPlieth: Akeso's Harmoni-6 wins on survival. Now on to $SMMT Harmoni-3. Via @ApexOnco from #ASCO26 -> https://t.co/9Nj3NTaAI9 $BNTX…
RT @KalantriShreyas: HARMONi-6 at #ASCO26: Ivonescimab + chemo improved OS vs tislelizumab + chemo in 1L advanced squamous NSCLC. mOS 27.9…
ASCO26 First Look Video: Dr. Monty Pal on HARMONi-6 Improvement of about 4 months in overall survival. Not a promise any longer. This is a new standard in lung cancer Will post full set of slides soon https://t.co/P4DBhK9N52 #ASCO26 @OncoAlert @OncBrothers @StephenVLiu
gilberto lopes on DeLLphi-305
🚨 Major SCLC results at #ESMO26! Phase III DeLLphi-305 (N=563): tarlatamab + durvalumab vs durvalumab 1L maintenance in ES-SCLC. Median OS: 21.1 vs 12.7 mo HR 0.42 (95% CI 0.32–0.54) 12-mo OS: 79.4% vs 53.3% An important survival advance. #LCSM https://t.co/WhlgNCfDyQ
Five lung cancer trials to watch at #ESMO26: DeLLphi-305 KRAScendo 1 SAFFRON OptiTROP-Lung04 OptiTROP-Lung06 Encouraging signals. Full data matter: survival, CNS activity, toxicity and quality of life. Figure separates published evidence from sponsor toplines. #LCSM https://t.co/3dtKr4eQ5q
Visual summary of today’s phase 3 DeLLphi-305 update in ES-SCLC: tarlatamab + durvalumab maintenance improved OS vs durvalumab alone after induction durvalumab + platinum/etoposide. PFS and ORR also positive. Full data still needed. #SCLC #LCSM https://t.co/pyeQbPyoRc
gilberto lopes on TAISHAN-302
Major positive #WCLC26 result in relapsed SCLC: TAISHAN-302. Tambotatug pelitecan (Tam-Peli) vs topotecan: • OS 13.3 vs 9.4 mo, HR 0.46 • PFS 7.4 vs 2.8 mo, HR 0.29 • ORR 59.1% vs 9.7% • intracranial response 32% vs 3% • grade 3+ AEs 55.4% vs 77.9% My take: a major positive randomized phase 3 trial and a potential new 2L option in SCLC. Important caveat: this was a China-only study, so broader global validation still matters. Sequencing vs tarlatamab also remains an open question. #LungCancer #SCLC #ThoracicOncology #ClinicalTrials
Two B7-H3 ADCs presented at #WCLC26 produced very encouraging results in relapsed SCLC: ARTEMIS-008 (Ris-Rez) and TAISHAN-302 (Tam-Peli). We put them side by side in a descriptive cross-trial comparison. https://t.co/yjHAxmq7S1
What looks different? TAISHAN-302 appears to have enrolled a somewhat higher-risk population, with more brain and liver metastases and a shorter chemotherapy-free interval. There were also differences in follow-up, PFS assessment/reporting, and safety reporting.
gilberto lopes on CROWN
Alright - day 1 was a great start for #ASCO26. Here’s my #LCSM summary 6 trials that matter, in one thread 1️⃣ CROWN — 7-yr lorlatinib 2️⃣ AcceleRET-Lung — pralsetinib 3️⃣ Lunbotinib P2 — next-gen RET 4️⃣ OptiTROP-Lung05 — sac-TMT + pembro 5️⃣ WU-KONG28 — sunvozertinib 6️⃣ CHRYSALIS-2 https://t.co/ZSY4CSL9Py
Lorlatinib reigns as frontline standard CROWN (Abs 8502): 7-yr lorlatinib vs crizotinib, 1L ALK+ NSCLC. Median PFS still not reached vs 9.1 mo; HR 0.19  — 55% vs 3% progression-free at 7 years , the longest PFS ever reported in advanced NSCLC. No new CNS progression after 30 https://t.co/FKmGlr2WPG
Block 2 - ALK and RET 8502 — Lorlatinib vs crizotinib, first-line ALK+, 7-year CROWN update. Mok, CUHK. The longest follow-up in oncogene-driven NSCLC; the durability question for frontline lorlatinib. •8503 — ALKOVE-1: neladalkib (NVL-655) in advanced ALK+. Lin, Mass General
gilberto lopes on SAFFRON
🚨 Important EGFR-mutated NSCLC results at #ESMO26! Phase III SAFFRON (N=338): Osimertinib + savolitinib vs platinum–pemetrexed after osimertinib progression, with high MET overexpression and/or amplification. OS: 17.8 vs 12.9 mo HR 0.68 (95% CI 0.50–0.91) https://t.co/KF8sZMbyxb
PFS: 7.6 vs 5.4 mo HR 0.55 (0.42–0.72) #LCSM Additional SAFFRON results: ORR: 51% vs 27% 12-mo OS: 70% vs 53% MET-amplified subgroup: PFS: 7.6 vs 4.2 mo HR 0.487 (0.35–0.66) Subgroup not formally tested. Grade ≥3 TEAEs: 64% vs 63%.
Five lung cancer trials to watch at #ESMO26: DeLLphi-305 KRAScendo 1 SAFFRON OptiTROP-Lung04 OptiTROP-Lung06 Encouraging signals. Full data matter: survival, CNS activity, toxicity and quality of life. Figure separates published evidence from sponsor toplines. #LCSM https://t.co/3dtKr4eQ5q
gilberto lopes on KRASCENDO-1
🚨 Major KRAS G12C NSCLC results at #ESMO26! Phase III Krascendo 1 (N=338): divarasib vs sotorasib/adagrasib. OS: 17.7 vs 12.0 mo HR 0.56 (95% CI 0.41–0.78) PFS: 9.8 vs 5.7 mo HR 0.58 (0.44–0.76) An important randomized survival advance. #LCSM More from Krascendo 1: https://t.co/YwjhBFcDcJ
Five lung cancer trials to watch at #ESMO26: DeLLphi-305 KRAScendo 1 SAFFRON OptiTROP-Lung04 OptiTROP-Lung06 Encouraging signals. Full data matter: survival, CNS activity, toxicity and quality of life. Figure separates published evidence from sponsor toplines. #LCSM https://t.co/3dtKr4eQ5q
One of my most anticipated #ESMO26 presentations: Krascendo 1 (LBA5) — phase III divarasib vs sotorasib/adagrasib in previously treated KRAS G12C+ NSCLC. Roche reports positive PFS and interim OS results. But the effect sizes and full safety data are still pending. https://t.co/9UNJGb7NmH
gilberto lopes on REZILIENT3
Three positive first-line phase III trials now shape EGFR exon 20 insertion NSCLC: • PAPILLON: amivantamab + chemo • WU-KONG 28: sunvozertinib • REZILIENT 3: zipalertinib + chemo No head-to-head winner. No clear OS winner yet. https://t.co/0jo6u0aVJa
#WCLC26: REZILIENT 3 in 1L EGFR exon20+ NSCLC. Zipalertinib + chemo vs chemo: • PFS 14.5 vs 8.5 mo • HR 0.50 (95% CI 0.34–0.73) • P=0.00015 • ORR 65.0% vs 40.3% • DoR 14.2 vs 9.9 mo https://t.co/R8mphMmV0c
4/6 ⚡ REZILIENT3 And immediately after PAPILLON comes a potential challenger: zipalertinib + chemotherapy in first-line EGFR exon20ins NSCLC. We already know from the public topline announcement: ✅ REZILIENT3 met its primary PFS endpoint. But we don’t know the numbers. At
gilberto lopes on ARROS-1
Sylvester Thoracic Working Group at #WCLC26 — Co-authored Presentation ARROS-1: zidesamtinib in TKI-naïve ROS1+ NSCLC. • ORR 94% • CR 15% • median DOR NR https://t.co/FtAnSDF5Si
Caveat: ARROS-1 is a single-arm phase 1/2 study. These data strongly support frontline development, but randomized confirmation matters before defining a new standard.
5/6 ARROS-1 One I’m particularly looking forward to — and I’m pleased to be a co-author. Zidesamtinib is a next-generation ROS1 inhibitor designed for potent CNS activity and resistance coverage. Preliminary TKI-naïve ARROS-1 data were striking: ORR 89% Intracranial ORR 83%
gilberto lopes’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Pleasant Surprise from #ASCO26 Abstract 8002 (LORIN): neoadjuvant lorlatinib in stage III ALK+ NSCLC hits a pCR of 46.9% and MPR of 81.3% — pathologic responses we rarely see with neoadjuvant TKIs. 75% of initially unresectable pts converted to surgery. Targeted neoadj earning its seat. #LCSM @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @COlazagasti
Here is an algorithm for RET fusion–positive NSCLC: evolving adjuvant and metastatic targeted therapies on @OpenMedicineHQ. Interactive, evidence-linked, open for discussion. Feedback welcome. #LivingAlgorithms https://t.co/ETNDBbf5Uc #ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti @openevidence @openmedicinehq @narjustflorezmd @lungoncdoc @drshieldsmd @jackwestmd @n8pennell @mtmdphd @drarturoai @larvol @onclive @rmanochakian @devikadasmd @dryukselurun @dan_morgen @ptarantinomd @DrJNaidoo @NaglaAKarimMD @Lung_Cancers @DrSanjayPopat @tnewsomdavis @Tony_Calles @ns_chd @BalazsHalmosMD @dr_yakupergun @ipreeshagul @FordePatrick @OncNewsCentral @imedverse @acmoorephd @DipeshUpretyMD @Alfdoc2 @g_mountzios @dmavicente @drshieldsmd @DrRiyazShah
#ASCO26 Conceptually striking data (Abstract 8517, ARCHER): a prophylactic peptide vaccine (ALK-Vac) targeting 7 ALK resistance mutations BEFORE they emerge, given alongside TKI in MRD. T-cell responses in 71%, DCR 93%, no grade ≥3 events. Tellingly, the lone progressor escaped via KRAS G12D — not ALK. #LCSM @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti @JohnsHopkins @KimmelCancerCtr
And, as we are talking RET, The new kid on the block: LUNBOTINIB. We have the trial open @SylvesterCancer in Miami. Impressive #ASCO26 data (Abstract 8505): lunbotinib, a next-gen brain-penetrant RET inhibitor, posts ORR 87% in PRE-TREATED RET+ NSCLC (mPFS 27.5 mo) & 81% treatment-naïve, with deep CNS activity — 6 complete intracranial responses per cohort. The pre-treated number outshining naïve is the surprise. #LCSM @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti @ellipsespharma
Here we go with our second tweet on @iaslc #wclc26 prep! 1/6 If Presidential Symposium 1 at #WCLC26 is eclectic, Symposium 2 has a remarkably clear theme: Targeted therapy moving earlier — and getting better. ADAURA → PAPILLON → REZILIENT3 → ARROS-1. Here’s what we already know — and what Monday morning in Seoul should tell us @OncoAlert @OncBrothers @oncodaily @Jani_Chinmay @Latinamd @COlazagasti
Industry Payments
CMS Open Payments · 2025 general payments
$28,812 across 14 payments